Thalys(SH:603716)2025-04-28 10:30Financial Performance - The company reported a revenue of CNY 287.43 million for Q1 2025, a decrease of 40.75% compared to CNY 485.12 million in the same period last year[4]. - The net profit attributable to shareholders was a loss of CNY 14.32 million, down from a profit of CNY 3.16 million in the previous year, representing a decline of 553.66%[4]. - The company's cash flow from operating activities was negative CNY 50.63 million, compared to negative CNY 27.15 million in the same period last year[4]. - Total operating revenue for Q1 2025 was ¥287,429,208.68, a decrease of 40.7% compared to ¥485,121,921.87 in Q1 2024[22]. - Net profit for Q1 2025 was a loss of ¥11,765,669.24, compared to a profit of ¥14,336,396.76 in Q1 2024[23]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.07, compared to ¥0.02 in Q1 2024[24]. Assets and Liabilities - The company’s total assets decreased by 19.74% to CNY 2.27 billion from CNY 2.83 billion at the end of the previous year[5]. - Total liabilities decreased to ¥1,330,358,087.98 in Q1 2025 from ¥1,868,026,362.40 in Q1 2024, a reduction of 28.7%[19]. - The total equity attributable to shareholders decreased to ¥920,025,332.15 in Q1 2025 from ¥934,292,086.63 in Q1 2024, a decline of 1.5%[19]. - The total cash and cash equivalents at the end of Q1 2025 were $165.72 million, slightly down from $169.65 million at the end of Q1 2024[28]. Cash Flow - The company’s cash flow statement for Q1 2025 is unaudited, indicating ongoing financial assessments[25]. - In Q1 2025, the cash inflow from operating activities was $355.44 million, a decrease of 37% compared to $565.54 million in Q1 2024[26]. - The net cash outflow from operating activities in Q1 2025 was $50.63 million, worsening from a net outflow of $27.15 million in Q1 2024[27]. - The net cash flow from investing activities in Q1 2025 was $44.30 million, a significant improvement from a net outflow of $3.65 million in Q1 2024[27]. - The cash inflow from financing activities in Q1 2025 was $42.51 million, compared to $38.80 million in Q1 2024, reflecting a 9% increase[28]. - The net cash outflow from financing activities in Q1 2025 was $35.42 million, an improvement from a net outflow of $63.39 million in Q1 2024[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 46,600[13]. - The largest shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 21,642,540 shares, accounting for 11.33% of total shares[13]. - The top ten shareholders include various institutional and individual investors, with no significant changes in their holdings reported[15]. Research and Development - The company plans to increase R&D investment in smart hospital construction, IoT applications, and big data analysis platforms, which has led to a 43.54% increase in R&D expenses[10]. - The company's R&D expenses increased to ¥13,980,853.82 in Q1 2025, up 43.5% from ¥9,739,943.89 in Q1 2024[22]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[15]. Other Financial Metrics - The company reported a non-recurring gain of CNY 14.14 million, primarily from the disposal of non-current assets[8]. - Total expenses (selling, administrative, and financial) were CNY 74.59 million, a reduction of 5.11% compared to the same period last year[6]. - The weighted average return on equity was -1.68%, down from 0.28% in the same period last year, a decrease of 1.96 percentage points[5]. - The company reported an investment income of ¥11,670,780.29 in Q1 2025, compared to a loss of ¥3,391,747.83 in Q1 2024[23].